ERBB2 and breast carcinoma: Similarly, Mogica et al., found that a reduced HER2 expression by ICH following neoadjuvant trastuzumab/pertuzumab-containing chemotherapy was associated with lower recurrence rates in HER2 ICH 3+ breast cancer [17].